レフルノミド 化学特性,用途語,生産方法
外観
白色～ほとんど白色粉末～結晶
効能
抗リウマチ薬, ジヒドロオロト酸脱水素酵素阻害薬
商品名
アラバ (サノフィ)
説明
Leflunomide is an orally-available disease-modifying antirheumatic drug
and was launched as Arava in the US for the treatment of rheumatoid arthritis
(RA) ; it is the first and only drug to be indicated to slow down structural joint
damage of RA, so addressing an unmet medical need.
Leflunomide is prepared in 3 steps from the appropriate acetoacetic anilide
using a nitrile oxide- enamine cycloaddition reaction to assemble the isoxazole
ring. Leflunomide is a prodrug, being extensively metabolized in vivo into the
corresponding 2-cyano-3-hydroxy-2-butenamide resulting from fragmentation of
the isoxazole ring. This cyanoenol is actually the active metabolite and several
experiments in animals have demonstrated that after oral administration,
substantial and sustained levels of this metabolite were delivered to the
systemic circulation.
In vitro, Leflunomide’s active metabolite inhibits dihydroorotate dehydrogenase,
an enzyme involved in the biosynthesis of pyrimidine nucleotides, probably
accounting for its immunosuppressive effect in vivo. Other mechanisms of action
such as inhibition of tyrosine kinase and inhibition of responsiveness to
interleukin-2 have been proposed. In diverse models of autoimmune or allergic
diseases, Leflunornide showed efficacy both prophylactically and therapeutically.
化学的特性
Off White Crystalline Solid
使用
By virtue of its immunosuppressant effects, leflunomide has found use in organ transplantation and treatment of rheumatoid arthritis and other autoimmune diseases.
定義
ChEBI: A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
適応症
Leflunomide (Arava) is an isoxazole derivative approved
for the treatment of rheumatoid arthritis in
1998. Limited data suggest that it is comparable in efficacy
to sulfasalazine and produces fewer adverse effects.
It has a faster onset of action (4 weeks) than other
DMARDs.
生物学の機能
Leflunomide is inactive, but teriflunomide inhibits pyrimidine de novo synthesis at low therapeutic doses by inhibiting
dihydroorotate dehydrogenase (the rate-determining enzyme for the synthesis of UMP), decreasing DNA and RNA
synthesis, and arresting the cell proliferation cycle and production of antibodies. The reduction of dihydroorotate to
orotate occurs concurrently with the reduction of its cofactor, ubiquinone (coenzyme Q). The inhibition of
dihydroorotate dehydrogenase by teriflunomide demonstrates noncompetitive and uncompetitive kinetics.
Administration of leflunomide in patients with rheumatoid arthritis results in progressive removal of B cells and
down-regulation of the immune process. Teriflunomide not only inhibits B-cell proliferation but also T-cell
proliferation, blocking the synthesis of immunosuppressive cytokines. At high therapeutic doses, leflunomide inhibits
protein tyrosine kinases.
一般的な説明
Leflunomide (Arava), an isoxazole prodrug, is an orally activeDMARD marketed in 1998 for the treatment of RA. Itis well absorbed and extensively metabolized in vivo to itsactive metabolite, 2-cyano-3-hydroxy-2-buteneamide (teriflunomide),resulting from a reductive ring opening of theisoxazole ring. Unlike MTX, teriflunomideblocks T-cell proliferation by inhibiting dihydroorotate dehydrogenase,the rate-limiting enzyme in the de novobiosynthesis of pyrimidine that is believed to be responsiblefor the immunosuppressive properties of leflunomide.For this reason, it is not surprising that leflunomide has avery comparable therapeutic efficacy to the first-lineDMARD, MTX as shown in several extended open clinicaltrials. However, even though leflunomide is well toleratedlike MTX, several cases of toxic neuropathy have beenobserved during its use, thus careful monitoring of the patient’sneurological status during treatment is mandatory.Like MTX, leflunomide is contraindicated in pregnancy orin women considering pregnancy.
生物活性
Immunosuppressant agent. In vitro the active metabolite A77 1726 (RS-61980) inhibits dihydroorotate dehydrogenase (K i = 2.7 μ M) and de novo pyrimidine synthesis in T-cells; blocks lymphocyte cell cycle progression and proliferation. A77 1726 also inhibits anti-CD3/CD28-induced cytokine production in PBMC cells (IC 50 = 21-27 μ g/ml). In vivo reduces inflammation in several animal models of autoimmune disease, arthritis, asthma and graft rejection.
薬物動態学
Leflunomide is a pro-drug that is rapidly and almost completely metabolized (half-life, <60 minutes) following oral
administration to teriflunomide, the pharmacologically active α-cyanoenol metabolite. The C3-H of the
isoxazole ring is essential for the ring opening to its active metabolite. The reaction is similar to CYP1A2-catalyzed
dehydration of aldoximes. The exact mechanism of action of leflunomide in the management of rheumatoid arthritis
has not been fully elucidated but appears to principally involve inhibition of B-lymphocyte (B-cell) proliferation,
reducing antibody formation. Activated lymphocytes must proliferate and synthesize large quantities of cytokines,
requiring increased de novo synthesis of uridine monophosphate (UMP) and other pyrimidine nucleotides for its cell
life cycle. Therefore, any substance that reduces the intracellular concentration of pyrimidine nucleotides will affect
the growth of these activated cells.
薬理学
Leflunomide is a prodrug that is converted to an active
malonitrilamide metabolite, A77 1726 (M1). M1 inhibits
T-cell proliferation by blocking de novo pyrimidine synthesis
and inhibiting the tyrosine kinases that are associated
with certain cytokine and growth factor receptors.
臨床応用
Leflunomide is a DMARD with anti-inflammatory and immunosuppressive activity used for the management of
rheumatoid arthritis. It retards structural damage associated with arthritis in adults who have moderate to severe
active rheumatoid arthritis. Leflunomide also is being investigated for use in patients with solid tumors and organ
transplant recipients.
副作用
Diarrhea occurs in approximately one-third of patients
taking this drug; indigestion, nausea, and vomiting occur
in about 10%. Other common adverse effects include
weight changes, headache, skin rashes, pruritus, and reversible
alopecia and hepatic enzyme elevation.Although
leflunomide acts as an immunosuppressive, it does not appear
to cause significant bone marrow depression.
予防処置
Leflunomide is teratogenic in animal models; it is absolutelycontraindicated in pregnancy, in women whomay become pregnant, and in breast-feeding women.Because of its long half-life, the M1 metabolite ofleflunomide may remain in the body for up to 2 years;therefore, a drug elimination procedure using cholestyramineshould be used before any attempt at pregnancy.This drug is not recommended for use in children.Caution should be used when administering thisdrug to individuals with renal or hepatic disease, heavyalcohol use, or immunosuppression.
The long half-life of leflunomide must be taken intoaccount to prevent drug interactions. Hepatotoxicity ispossible if leflunomide is given in conjunction with a hepatotoxicagent such as methotrexate or certain NSAIDs.Leflunomide inhibits CYP2C9, the enzyme responsiblefor the metabolism of numerous drugs. Rifampin inducesthe P450 enzyme responsible for converting leflunomide to its M1 metabolite.Cholestyramine enhances the clearanceof leflunomide and its M1 metabolite.
レフルノミド 上流と下流の製品情報
原材料
準備製品